Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1
- 1 August 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 11 (6) , 511-520
- https://doi.org/10.1097/00008571-200108000-00006
Abstract
N-acetyltransferase 1 (NAT1) catalyses the activation and/or deactivation of aromatic and heterocyclic amine carcinogens. A genetic polymorphism in NAT1 is associated with an increased risk of various cancers and drug toxicities, but epidemiological investigations are severely compromised by a poor understanding of the relationship between NAT1 genotype and phenotype. Human reference NAT1*4 and 12 known human NAT1 allelic variants possessing nucleotide polymorphisms in the NAT1 coding region were cloned and expressed in yeast (Schizosaccharomyces pombe). Large reductions in N- and O-acetyltransferase catalytic activities were observed for recombinant NAT1 allozymes encoded by NAT1*14B, NAT1*15, NAT1*17, NAT1*19 and NAT1*22. Each of these alleles exhibited NAT1 protein expression levels below the limit of detection as measured by Western blot. No differences between high and low activity NAT1 alleles were observed in relative mRNA expression or relative transformation efficiency. The recombinant NAT1 17 and NAT1 22 allozymes showed reduced intrinsic stability when compared with NAT1 4. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) N-acetylation was not catalysed by any of the NAT1 allozymes. Large differences in the metabolic activation via O-acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-hydroxy-PhIP) were noted for NAT1 allelic variants. The results of these studies suggest an important role for the NAT1 genetic polymorphism in metabolism of aromatic and heterocyclic amine carcinogens. Furthermore, these results suggest that low NAT1 phenotype results from NAT1 allelic variants that encode reduced expression of NAT1 and/or less-stable NAT1 protein.Keywords
This publication has 24 references indexed in Scilit:
- Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphismsPharmacogenetics, 2001
- Characterization of Naturally Occurring and Recombinant HumanN-Acetyltransferase Variants Encoded byNAT1*Molecular Pharmacology, 2000
- Substrate-Dependent Regulation of Human ArylamineN-Acetyltransferase-1 in Cultured CellsMolecular Pharmacology, 2000
- Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1)Biochemical Pharmacology, 1999
- Functional polymorphism of the human arylamine JV-acetyltransferase type 1 gene caused by C190T and G560A mutationsPharmacogenetics, 1998
- Identification of a Novel Allele at the HumanNAT1Acetyltransferase LocusBiochemical and Biophysical Research Communications, 1997
- Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyltransferase encoding genes of the Syrian hamsterPharmacogenetics, 1996
- Polymorphic arylamine N-acetyltransferase encoding gene (NAT2) from homozygous rapid and slow acetylator congenic Syrian hamstersGene, 1994
- Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferasesCarcinogenesis: Integrative Cancer Research, 1993
- Genomic sequencing.Proceedings of the National Academy of Sciences, 1984